Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | GCG | P01275 | 3/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22199079 | 0.80 | NR2E1 (0.43) | CYP3A4CYP2D6CYP2C19HDAC11HDAC8 | |
| SCHEMBL22185898 | 0.78 | GCG (0.30) | GCG | |
| SCHEMBL22185897 | 0.74 | CYP2E1 (0.36) | — | |
| SCHEMBL22185905 | 0.74 | APLNR (0.35) | GCG | |
| SCHEMBL12197725 | 0.73 | CYP3A4 (0.43) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL22186145 | 0.69 | IDH1 (0.44) | TSHR | |
| SCHEMBL22184960 | 0.69 | PANK3 (0.37) | GCG | |
| SCHEMBL11901185 | 0.69 | GCG (0.36) | GCG | |
| SCHEMBL179297 | 0.68 | CYP2E1 (0.42) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24724318 | 0.66 | TRPV4 (0.36) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | CYP3A4 1010/4885CYP2D6 524/4885TSHR 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.